Intensity Therapeutics, Inc. Common stock
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical tr… Read more
Intensity Therapeutics, Inc. Common stock (INTS) - Net Assets
Latest net assets as of September 2025: $7.22 Million USD
Based on the latest financial reports, Intensity Therapeutics, Inc. Common stock (INTS) has net assets worth $7.22 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($9.59 Million) and total liabilities ($2.36 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $7.22 Million |
| % of Total Assets | 75.35% |
| Annual Growth Rate | -17.63% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 21.21 |
Intensity Therapeutics, Inc. Common stock - Net Assets Trend (2019–2024)
This chart illustrates how Intensity Therapeutics, Inc. Common stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Intensity Therapeutics, Inc. Common stock (2019–2024)
The table below shows the annual net assets of Intensity Therapeutics, Inc. Common stock from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $2.92 Million | -77.83% |
| 2023-12-31 | $13.16 Million | +187.18% |
| 2022-12-31 | $-15.10 Million | -73.86% |
| 2021-12-31 | $-8.68 Million | -457.27% |
| 2020-12-31 | $-1.56 Million | -120.24% |
| 2019-12-31 | $7.70 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Intensity Therapeutics, Inc. Common stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4963796900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.07% |
| Other Components | $69.70 Million | 2388.59% |
| Total Equity | $2.92 Million | 100.00% |
Intensity Therapeutics, Inc. Common stock Competitors by Market Cap
The table below lists competitors of Intensity Therapeutics, Inc. Common stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
INITECH Co. Ltd
KQ:053350
|
$15.03 Million |
|
Ora Gold Ltd
AU:OAU
|
$15.03 Million |
|
Future Metals NL
PINK:FMELF
|
$15.04 Million |
|
Sewha P&C INC
KQ:252500
|
$15.04 Million |
|
Firetail Resources Ltd
AU:FTL
|
$15.03 Million |
|
Hopscotch Groupe S.A.
PA:ALHOP
|
$15.03 Million |
|
SFP Tech Holdings Bhd
KLSE:0251
|
$15.02 Million |
|
CrowdWorks, Inc.
KQ:355390
|
$15.02 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Intensity Therapeutics, Inc. Common stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 13,162,000 to 2,918,000, a change of -10,244,000 (-77.8%).
- Net loss of 16,268,000 reduced equity.
- New share issuances of 3,232,000 increased equity.
- Other comprehensive income increased equity by 17,295,000.
- Other factors decreased equity by 14,503,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-16.27 Million | -557.51% |
| Share Issuances | $3.23 Million | +110.76% |
| Other Comprehensive Income | $17.30 Million | +592.7% |
| Other Changes | $-14.50 Million | -497.02% |
| Total Change | $- | -77.83% |
Book Value vs Market Value Analysis
This analysis compares Intensity Therapeutics, Inc. Common stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 30.93x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 11.04x to 30.93x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $0.59 | $6.49 | x |
| 2020-12-31 | $-0.12 | $6.49 | x |
| 2021-12-31 | $-0.66 | $6.49 | x |
| 2022-12-31 | $-1.15 | $6.49 | x |
| 2023-12-31 | $0.96 | $6.49 | x |
| 2024-12-31 | $0.21 | $6.49 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Intensity Therapeutics, Inc. Common stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -557.51%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.64x
- Recent ROE (-557.51%) is below the historical average (-117.58%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -67.92% | 0.00% | 0.00x | 1.17x | $-6.00 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.80 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.02 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-6.07 Million |
| 2023 | -80.06% | 0.00% | 0.00x | 1.31x | $-11.85 Million |
| 2024 | -557.51% | 0.00% | 0.00x | 1.64x | $-16.56 Million |
Industry Comparison
This section compares Intensity Therapeutics, Inc. Common stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Intensity Therapeutics, Inc. Common stock (INTS) | $7.22 Million | -67.92% | 0.33x | $15.03 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |